Evidence map›Paper›PMID 29210198›Full record

ReviewStem cells translational medicine2018

Concise Review: Quantitative Detection and Modeling the In Vivo Kinetics of Therapeutic Mesenchymal Stem/Stromal Cells.

Anastasia Brooks, Kathryn Futrega, Xiaowen Liang, Xiaoling Hu, Xin Liu, Darrell H G Crawford, Michael R Doran, Michael S Roberts, Haolu Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Persistency of Mesenchymal Stromal/Stem Cells in Lungs.Frontiers in cell and developmental biology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anastasia BrooksTherapeutics Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Kathryn FutregaInstitute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia.
Xiaowen LiangTherapeutics Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Xiaoling HuTherapeutics Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Xin LiuTherapeutics Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Darrell H G CrawfordSchool of Clinical Medicine, The University of Queensland, Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, Australia.
Michael R DoranMater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.
Michael S RobertsTherapeutics Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Haolu WangTherapeutics Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.ORCID 0000-0003-4935-1103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) present a promising tool in cell-based therapy for treatment of various diseases. Currently, optimization of treatment protocols in clinical studies is complicated by the variations in cell dosing, diverse methods used to deliver MSCs, and the variety of methods used for tracking MSCs in vivo. Most studies use a dose escalation approach, and attempt to correlate efficacy with total cell dose. Optimization could be accelerated through specific understanding of MSC distribution in vivo, long-term viability, as well as their biological fate. While it is not possible to quantitatively detect MSCs in most targeted organs over long time periods after systemic administration in clinical trials, it is increasingly possible to apply pharmacokinetic modeling to predict their distribution and persistence. This Review outlines current understanding of the in vivo kinetics of exogenously administered MSCs, provides a critical analysis of the methods used for quantitative MSC detection in these studies, and discusses the application of pharmacokinetic modeling to these data. Finally, we provide insights on and perspectives for future development of effective therapeutic strategies using pharmacokinetic modeling to maximize MSC therapy and minimize potential side effects. Stem Cells Translational Medicine 2018;7:78-86.

Indexed as

Cell- and Tissue-Based TherapyCell DifferentiationHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationModels, TheoreticalKineticsModelingQuantitative detectionStem cells

Identifiers

PMID29210198
PMCPMC5746161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.